SHMT2 and breast carcinoma: Moreover, SHMT2 has been found to be associated with a poor prognosis in hepatocellular carcinoma (Ji et al., 2019), intrahepatic cholangiocarcinoma (Ning et al., 2018), breast cancer (Bernhardt et al., 2017) and gastrointestinal tumors (Liu et al., 2019).